Arrowhead Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: Annual Revenue Growth Compared

Biotech Revenue Race: Arrowhead vs. Celldex from 2014-2023

__timestampArrowhead Pharmaceuticals, Inc.Celldex Therapeutics, Inc.
Wednesday, January 1, 20141750003586000
Thursday, January 1, 20153820005480000
Friday, January 1, 20161583336786000
Sunday, January 1, 20173140770912743000
Monday, January 1, 2018161423219538000
Tuesday, January 1, 20191687955773573000
Wednesday, January 1, 2020879920667418000
Friday, January 1, 20211382870004651000
Saturday, January 1, 20222432310002357000
Sunday, January 1, 20232407350006883000
Monday, January 1, 20243551000
Loading chart...

Cracking the code

A Tale of Two Biotechs: Revenue Growth from 2014 to 2023

In the dynamic world of biotechnology, Arrowhead Pharmaceuticals, Inc. and Celldex Therapeutics, Inc. have charted distinct paths over the past decade. From 2014 to 2023, Arrowhead Pharmaceuticals has demonstrated a remarkable revenue growth trajectory, with a staggering increase of over 138,000% from its humble beginnings in 2014. This growth peaked in 2022, with revenues reaching their zenith, showcasing Arrowhead's strategic advancements in RNA interference therapeutics.

Conversely, Celldex Therapeutics has experienced a more modest revenue journey, with fluctuations reflecting the volatile nature of drug development and market conditions. Despite a peak in 2017, Celldex's revenue saw a decline, highlighting the challenges faced in the competitive biotech landscape.

This comparison underscores the diverse strategies and market responses of these two companies, offering valuable insights into the biotech industry's evolving dynamics.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025